Ali Moshfegh

Publikationer
Forskningsbidrag
CV
Populärvetenskap och samverkan

Artiklar

Article: CANCERS. 2024;16(22):3821
A Small Molecule Antagonist of CX3CR1 (KAND567) Inhibited the Tumor Growth-Promoting Effect of Monocytes in Chronic Lymphocytic Leukemia (CLL)
Zhong W; Kokhaei P; Mulder TA; Ghaderi A; Moshfegh A; Lundin J; Palma M; Schultz J; Olin T; Osterborg A; Mellstedt H; Hojjat-Farsangi M
Article: IMMUNITY. 2023;56(5):979-997.e11
The RNA editor ADAR2 promotes immune cell trafficking by enhancing endothelial responses to interleukin-6 during sterile inflammation
Gatsiou A; Tual-Chalot S; Napoli M; Ortega-Gomez A; Regen T; Badolia R; Cesarini V; Garcia-Gonzalez C; Chevre R; Ciliberti G; Silvestre-Roig C; Martini M; Hoffmann J; Hamouche R; Visker JR; Diakos N; Wietelmann A; Silvestris DA; Georgiopoulos G; Moshfegh A; Schneider A; Chan W; Guenther S; Backs J; Kwak S; Selzman CH; Stamatelopoulos K; Rose-John S; Trautwein C; Spyridopoulos I; Braun T; Waisman A; Gallo A; Drakos SG; Dimmeler S; Sperandio M; Soehnlein O; Stellos K
Article: PHARMACEUTICS. 2023;15(4):1148
A Small Molecule Targeting the Intracellular Tyrosine Kinase Domain of ROR1 (KAN0441571C) Induced Significant Apoptosis of Non-Small Cell Lung Cancer (NSCLC) Cells
Ghaderi A; Okhovat M-A; Lehto J; De Petris L; Doulabi EM; Kokhaei P; Zhong W; Rassidakis GZ; Drakos E; Moshfegh A; Schultz J; Olin T; Osterborg A; Mellstedt H; Hojjat-Farsangi M
Article: HANDBOOK OF EXPERIMENTAL PHARMACOLOGY. 2021;269:75-99
Targeting the Receptor Tyrosine Kinase ROR1 by Small Molecules.
Hojjat-Farsangi M; Moshfegh A; Schultz J; Norin M; Olin T; Österborg A; Mellstedt H
Article: BIOMEDICINES. 2020;8(6):E170-170
ROR1 is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells
Ghaderi A; Daneshmanesh AH; Moshfegh A; Kokhaei P; Vagberg J; Schultz J; Olin T; Harrysson S; Smedby KE; Drakos E; Rassidakis GZ; Osterborg A; Mellstedt H; Hojjat-Farsangi M
Journal article: JOURNAL OF IMMUNOLOGY. 2020;204(1_Supplement):59.7
Reduced level of CX3CR1 positive T-cells and monocytes in children with, newly diagnosed, Type 1 diabetes
Dadfar E; Ghaderi A; Moshfegh A; Barcenilla H; Casas R; Samuelsson U
Article: LEUKEMIA. 2018;32(10):2291-2295
First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells
Hojjat-Farsangi M; Daneshmanesh AH; Khan AS; Shetye J; Mozaffari F; Kharaziha P; Rathje L-S; Kokhaei P; Hansson L; Vagberg J; Bystrom S; Olsson E; Lofberg C; Norstrom C; Schultz J; Norin M; Olin T; Osterborg A; Mellstedt H; Moshfegh A
Article: PLOS ONE. 2018;13(6):e0198038
A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib
Daneshmanesh AH; Hojjat-Farsangi M; Ghaderi A; Moshfegh A; Hansson L; Schultz J; Vagberga J; Bystrom S; Olsson E; Olin T; Osterborg A; Mellstedt H
Article: PLOS ONE. 2018;13(2):e0192839
Autologous T cells expressing the oncogenic transcription factor KLF6-SV1 prevent apoptosis of chronic lymphocytic leukemia cells
Kokhaei P; Hojjat-Farsangi M; Mozaffari F; Moshfegh A; Pak F; Rashidy-Pour A; Palma M; Hansson L; Osterborg A; Mellstedt H
Article: PLOS ONE. 2017;12(11):e0187294
Flavin-containing monooxygenase 3 (FMO3) role in busulphan metabolic pathway
El-Serafi I; Terelius Y; Abedi-Valugerdi M; Naughton S; Saghafian M; Moshfegh A; Mattsson J; Potacova Z; Hassan M
Article: BMC NEPHROLOGY. 2017;18(1):161
Vitamin D receptor activation reduces inflammatory cytokines and plasma MicroRNAs in moderate chronic kidney disease - a randomized trial
Mansouri L; Lundwall K; Moshfegh A; Jacobson SH; Lundahl J; Spaak J
Article: JOURNAL OF DIABETES AND ITS COMPLICATIONS. 2017;31(1):4-12
Mono-epoxy-tocotrienol-α enhances wound healing in diabetic mice and stimulates in vitro angiogenesis and cell migration
Xu C; Bentinger M; Savu O; Moshfegh A; Sunkari V; Dallner G; Swiezewska E; Catrina S-B; Brismar K; Tekle M
Article: ONCOLOGY LETTERS. 2016;12(4):2782-2788
Differential expression of viral agents in lymphoma tissues of patients with ABC diffuse large B-cell lymphoma from high and low endemic infectious disease regions
Hogfeldt T; Jaing C; Mc Loughlin K; Thissen J; Gardner S; Bahnassy AA; Gharizadeh B; Lundahl J; Osterborg A; Porwit A; Zekri A-RN; Khaled HM; Mellstedt H; Moshfegh A
Article: TUMOR BIOLOGY. 2016;37(9):11947-11957
Dishevelled proteins are significantly upregulated in chronic lymphocytic leukaemia
Khan AS; Hojjat-Farsangi M; Daneshmanesh AH; Hansson L; Kokhaei P; Osterborg A; Mellstedt H; Moshfegh A
Article: PLOS ONE. 2015;10(11):e0142310
Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia.
Hojjat-Farsangi M; Jeddi-Tehrani M; Daneshmanesh AH; Mozaffari F; Moshfegh A; Hansson L; Razavi SM; Sharifian RA; Rabbani H; Österborg A; Mellstedt H; Shokri F
Article: PLOS ONE. 2015;10(11):e0141979
Cytochrome P450 Oxidoreductase Influences CYP2B6 Activity in Cyclophosphamide Bioactivation
El-Serafi I; Afsharian P; Moshfegh A; Hassan M; Terelius Y
Article: PHARMACOGENOMICS JOURNAL. 2015;15(5):405-413
Cytochrome P450 2J2, a new key enzyme in cyclophosphamide bioactivation and a potential biomarker for hematological malignancies
El-Serafi I; Fares M; Abedi-Valugerdi M; Afsharian P; Moshfegh A; Terelius Y; Potacova Z; Hassan M
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2015;33(15_suppl):8556
A new class of anti-cancer drugs targeting the tyrosine kinase receptor ROR1 in CLL.
Mellstedt H; Khan S; Hojjat-Farsangi M; Daneshmanesh AH; Vagberg J; Bystrom S; Schultz J; Norin M; Olsson E; Lofberg C; Norstrom C; Olin T; Österborg A; Moshfegh A
Article: LEUKEMIA & LYMPHOMA. 2014;55(5):1158-1165
Expression of microRNA-1234 related signal transducer and activator of transcription 3 in patients with diffuse large B-cell lymphoma of activated B-cell like type from high and low infectious disease areas
Hoegfeldt T; Johnsson P; Grander D; Bahnassy AA; Porwit A; Eid S; Osterborg A; Zekri A-RN; Lundahl J; Khaled MH; Mellstedt H; Moshfegh A
Article: PLOS ONE. 2014;9(1):e86619
Cyclophosphamide Alters the Gene Expression Profile in Patients Treated with High Doses Prior to Stem Cell Transplantation
El-Serafi I; Abedi-Valugerdi M; Potacova Z; Afsharian P; Mattsson J; Moshfegh A; Hassan M
Visa fler

Alla övriga publikationer

Conference publication: JOURNAL OF IMMUNOLOGY. 2020;204(1)
Reduced level of CX3CR1 positive T-cells and monocytes in children with, newly diagnosed, Type 1 diabetes
Dadfar E; Ghaderi A; Moshfegh A; Barcenilla H; Casas R; Samuelsson U
Meeting abstract: BLOOD. 2019;134:5312
ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells
Mellstedt H; Ghaderi A; Aschan J; Mozaffari F; Moshfegh A; Sander B; Schultz J; Norin M; Olin T; Drakos E; Rassidakis GZ; Osterborg A; Hojjat-Farsangi M
Meeting abstract: BLOOD. 2019;134:2565
Diffuse Large B Cell Lymphoma (DLBCL) Expresses ROR1 and a ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Tumor Cells
Hojjat-Farsangi M; Ghaderi A; Daneshmanesh A; Lehto J; Moshfegh A; Kokhaei P; Vagberg J; Olsson E; Lofberg C; Norstrom CC; Schultz J; Norin M; Olin T; Drakos E; Rassidakis GZ; Osterborg A; Mellstedt H
Conference publication: PANCREAS. 2017;46(10):1396
ROR1 Targeting Drugs Induced Significant Apoptosis of Pancreatic Cancer Cells
Daneshmanesh AH; Hojjat-Farsangi M; Moshfegh A; Schultz J; Vagberg J; Bystrom S; Olsson E; Olin T; Osterborg A; Mellstedt H
Conference publication: KIDNEY INTERNATIONAL REPORTS. 2016;1(4):s14-s15
P30 VITAMIN D RECEPTOR ACTIVATION REDUCES INFLAMMATORY CYTOKINES AND PLASMA MICRORNAS IN MODERATE CHRONIC KIDNEY DISEASE–A RANDOMIZED TRIAL
Mansouri L; Lundwall K; Moshfegh A; Jacobson SH; Lundahl J; Spaak J
Meeting abstract: ANNALS OF ONCOLOGY. 2016;27:vi530
First generation of a small chemical molecule ROR1 RTK tyrosine kinase inhibitor
Mellstedt H; Hojjat-Farsangi M; Daneshmanesh AH; Moshfegh A; Bystrom S; Norin M; Olin T; Schultz J; Vagberg J; Osterborg A
Meeting abstract: BLOOD. 2015;126(23):2912
First-in-Class ROR1 Small Molecule Inhibitor (KAN0439834) Downregulated Wnt-Canonical and Non-Canonical Signaling Pathways and Induced Apoptosis of CLL Cells
Hojjat-Farsangi M; Moshfegh A; Daneshmanesh AH; Vagberg J; Styrbjorn B; Schultz J; Olsson E; Lofberg C; Norstrom C; Norin M; Olin T; Osterborg A; Mellstedt H
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2015;33(15)
A new class of anti-cancer drugs targeting the tyrosine kinase receptor ROR1 in CLL
Mellstedt H; Khan S; Hojjat-Farsangi M; Daneshmanesh AH; Vagberg J; Bystrom S; Schultz J; Norin M; Olsson E; Lofberg C; Norstrom C; Olin T; Tsterborg A; Moshfegh A
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2015;169(3):455-458
The PI3K/AKT/mTOR pathway is involved in direct apoptosis of CLL cells induced by ROR1 monoclonal antibodies.
Daneshmanesh AH; Hojjat-Farsangi M; Moshfegh A; Khan AS; Mikaelsson E; Österborg A; Mellstedt H
Conference publication: JOURNAL OF IMMUNOLOGY. 2015;194:132.6
Down regulation of genes related to selenium signaling pathway in in-vivo transmigrated neutrophils from patients with Chronic Kidney Disease
Mansour L; Moshfegh A; Hylander B; Jacobson S; Lundahi J
Conference publication: BLOOD. 2014;124(21):1150
Busulphan Metabolism Via Flavin-Containing Monooxygenase 3 (FMO3) Can Explain Several Interactions with Other Drugs
El Serafi I; Abedi-Valugerdi M; Naughton S; Saghafian M; Mattsson J; Moshfegh A; Terelius Y; Potacova Z; Hassan M
Review: SEMINARS IN CANCER BIOLOGY. 2014;29:21-31
The receptor tyrosine kinase ROR1-An oncofetal antigen for targeted cancer therapy
Hojjat-Farsangi M; Moshfegh A; Daneshmanesh AH; Khan AS; Mikaelsson E; Osterborg A; Mellstedt H
Meeting abstract: CANCER RESEARCH. 2014;74(19):4770
Anti-ROR1 monoclonal antibodies induce apoptosis in pancreatic cancer cells via the PI3-kinase/AKT/mTOR pathway
Daneshmanesh AH; Hojjat-Farsangi M; Moshfegh A; Mikaelsson E; Khan AS; Osterborg A; Mellstedt H
Meeting abstract: CANCER RESEARCH. 2014;74(19):3184
Differential expression of viral agents in lymphoma tissues of patients with ABC diffuse large B-cell lymphoma from high and low endemic infectious disease region
Moshfegh A; Hogfeldt T; Jaing C; Lundahl J; Osterborg A; Loughlin KM; Gardner SN; Gharizadeh B; Porwit A; Bahnassy AA; Zekri A-RN; Khaled HM; Mellstedt H
Conference publication: HAEMATOLOGICA. 2014;99:135
TARGETING THE TYROSINE KINASE RECEPTORS ROR1 AND AXL (RTKS) IN BURKITT'S LYMPHOMA
Hojjat-Farsangi M; Daneshmanesh AH; Khan AS; Moshfegh A; Wagberg J; Bystrom S; Schultz J; Olin T; Osterborg A; Mellstedt H
Conference publication: HAEMATOLOGICA. 2014;99:51-52
ANTI-ROR1 MONOCLONAL ANTIBODIES INDUCED APOPTOSIS OF CLL CELLS AND ALTERED PHOSPHORYLATION OF SRC AND PI3-KINASES
Daneshmanesh AH; Hojjat-Farsangi M; Moshfegh A; Mikaelsson E; Khan AS; Osterborg A; Mellstedt H
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2014;32(15):e13561
A new class of compound for pancreatic carcinoma targeting the tyrosine kinase receptor (TKR) ROR1.
Mellstedt H; Daneshmanesh AH; Moshfegh A; Farsangl MH; Khan S; Mlkaelsson E; Vagberg J; Systrom S; Schultz J; Olin T; Ostorborg A
Conference publication: HAEMATOLOGICA. 2013;98:511
GLOBAL GENE ARRAY ANALYSES TO IDENTIFY BIOMARKERS ASSOCIATED WITH CLINICAL OUTCOME IN ACUTE MYELOID LEUKEMIA
Lindberg M; Haag P; Moshfegh A; Kanter L; Lewensohn R; Viktorsson K; Stenke L
Conference publication: HAEMATOLOGICA. 2013;98:404
THE ROLE OF CYP2J2 IN CYCLOPHOSPHAMIDE METABOLISM
El-Serafi I; Afsharian P; Potacova Z; Terelius Y; Moshfegh A; Hassan M
Conference publication: HAEMATOLOGICA. 2013;98:290
ANTI-ROR1 MONOCLONAL ANTIBODY INDUCED APOPTOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA CELLS THROUGH PI3-KINASE/AKT/MTOR SIGNALING PATHWAY
Daneshmanesh AH; Hojjat-Farsangi M; Moshfegh A; Khan A; Jeddi-Tehrani M; Osterborg A; Mellstedt H
Visa fler

Forskningsbidrag

ROR1 - a tyrosine kinase receptor for targeted therapy
Swedish Research Council
1 januari 2013 - 31 december 2015

Anställningar

Anknuten till Forskning, Onkologi-Patologi, Karolinska Institutet, 2024-2027

Examina och utbildning

MEDICINE DOKTORSEXAMEN, Doktorexamen, The biological mechanisms in neutrophil and eosinophil adhesion and transmigration in vitro and theur relation to the inflammatory process in vivo, Institutionen för medicin, Solna, Karolinska Institutet, 2002
LICENTIATEXAMEN, INST F LABORATORIEMEDICIN (K5), Karolinska Institutet, 1999

Artiklar

Alla övriga publikationer

Forskningsbidrag

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI